Skip to main content

Unity Biotechnology, Inc. (UBX)

NASDAQ: UBX · IEX Real-Time Price · USD
2.25 -0.07 (-3.02%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap124.55M
Revenue (ttm)n/a
Net Income (ttm)-80.72M
Shares Out54.86M
EPS (ttm)-1.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume502,830
Open2.32
Previous Close2.32
Day's Range2.21 - 2.36
52-Week Range2.21 - 9.78
Beta0.22
AnalystsHold
Price Target6.86 (+204.9%)
Est. Earnings DateNov 4, 2021

About UBX

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related ey...

IndustryBiotechnology
IPO DateMay 3, 2018
CEOAnirvan Ghosh
Employees62
Stock ExchangeNASDAQ
Ticker SymbolUBX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for UBX stock is "Hold." The 12-month stock price forecast is 6.86, which is an increase of 204.89% from the latest price.

Price Target
$6.86
(204.89% upside)
Analyst Consensus: Hold

News

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag...

2 weeks ago - GlobeNewsWire

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for whom ant...

2 weeks ago - Benzinga

UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences

16 th Annual Citi BioPharma Conference on September 8-10, 2021

1 month ago - GlobeNewsWire

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag...

2 months ago - GlobeNewsWire

UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging...

2 months ago - GlobeNewsWire

UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates

UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-...

2 months ago - GlobeNewsWire

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Cli...

SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CH...

2 months ago - PRNewsWire

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag...

2 months ago - GlobeNewsWire

UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positi...

UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325

2 months ago - GlobeNewsWire

Takeaways On Unity Biotech's Clinical Data From A Bull Analyst

Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ:UBX).

3 months ago - Benzinga

UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates

-  UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity

5 months ago - GlobeNewsWire

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinica...

UBX1325's selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema

5 months ago - GlobeNewsWire

UNITY Biotechnology to Present Preclinical Data on Clinical Candidate Molecule UBX1325 at the Association for Researc...

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of ag...

5 months ago - GlobeNewsWire

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agin...

6 months ago - GlobeNewsWire

UNITY Biotechnology Reports Granting of New Employment Inducement Award

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of ag...

7 months ago - GlobeNewsWire

UNITY Biotechnology to Participate in Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of agi...

7 months ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?

Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.

9 months ago - Zacks Investment Research

Ascentage Pharma's Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for...

SUZHOU, China and ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, ch...

10 months ago - PRNewsWire

Unity Biotech, Aurinia Among Pharma Companies With R&D Flops in 2020

Big names like Glaxo, Pfizer and Johnson & Johnson also abandoned promising programs

Other symbols:AUPH
10 months ago - GuruFocus

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of agi...

10 months ago - GlobeNewsWire

UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O'Neill, M.B., to the ...

Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY's Board

10 months ago - GlobeNewsWire

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Unity Bio was previously advancing a lead candidate aimed at reducing osteoarthritis pain by selectively clearing senescent cells in the knee. This candidate, UBX0101, was dropped by the company on Augu...

10 months ago - Seeking Alpha

UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging,...

11 months ago - GlobeNewsWire

UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

SAN FRANCISCO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing disease...

1 year ago - GlobeNewsWire

UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

1 year ago - GlobeNewsWire